Endocannabinoids and liver disease

Hepatology

Volumn 41, Issue 5, 2005, Pages 983-985

  Jiménez, Wladimiro ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; RIMONABANT; VOLTAGE GATED CALCIUM CHANNEL;

APOPTOSIS; ARTERY DILATATION; ASCITES; BINDING AFFINITY; BIOLOGY; BLOOD PRESSURE; BRAIN REGION; CARDIOVASCULAR SYSTEM; CELL GROWTH; CELL VIABILITY; CONCENTRATION RESPONSE; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG SYNTHESIS; EDITORIAL; HUMAN; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASE; MESENTERIC ARTERY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY MECHANISM; STELLATE CELL; STIMULATION;

ANIMALS; ENDOCANNABINOIDS; HUMANS; LIVER DISEASES; RECEPTOR, CANNABINOID, CB1;

EID: 17844367093     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20714     Document Type: Editorial

References (24)

1. Walker JM, Krey, Chu CJ, Huang SM. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 2002;121: 159-172.
2. Van der Stelt M, Di Marzo V. Anandamide as an intracellular messenger regulating ion channel activity. Prostaglandins Other Lipid Mediat. doi:10.1016/j.prostaglandins.2004.09.007. Available online November 18, 2004.
3. McAllister SD and Glass M. CB1 and CB2 receptor-mediated signalling: a focus endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 2002; 66:161-171.
4. Zygmunt PM, Petersson J, Andersson BA, Chuang H, Sorgard M, DiMarzo V, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999;400:452-457.
5. Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1. Eur J Biochem 2004;271:1814-1819.
6. Deutsch DG, Goligorski MS, Schmid PC, Krebsbach RJ, Schmid HHO, Das SK, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997;100:1538-1546.
7. 2+ channel current. Am J Physiol 1999;276:H2085-H2093.
8. Asthon JC, Appleton I, Darlington CL, Smith PF. Immunohistochemical localization of cerebrovascular CB1 receptor protein. J Cardiovasc Pharmacol 2004; 44:517-519.
9. Ralevic, V, Kendall, DA, Randall, MD, Smart D. Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptor: roles in regulation of cardiovascular system. Life Science 2002;71:2577-2594.
10. Hiley CR, Ford WR. Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol Rev 2004;79:187-205.
11. Guzman M. Cannabinoids: potential anticancer agents. Nature Rev Cancer 2003;3:745-755.
12. Hillard JC, Jarrahian A. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids 2000;108: 123-134.
13. Sugiura T, Kobayashi Y, Oka S, Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids 2002;66:173-192.
14. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004;141:765-774.
15. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discovery 2004;3:771-782.
16. Batkai S, Jarai Z, Wagner JA, Goparaiu SK, Varga K, Liu J, et al. Endocannabinoids acting at vascular CB1 receptor mediate the vasodilatated state in advanced liver cirrhosis. Nat Med. 2001;7:827-832.
17. Ros J, Clària J, To-Figueras J, Planagumà A, Cejudo-Martín P, Fernández-Varo G, Martín-Ruiz R, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002;122:85-93.
18. Fernández-Rodriguez CM, Romero J, Petros TJ, Bradshaw H, Gasalla JM, Gutiérrez ML, et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver International 2004;24:477-483.
19. Domenicali M, Ros J, Fernández-Varo G, Cejudo-Martín P, Crespo M, Morales-Ruiz M, et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut 2005;54:522-527.
20. Gaskary SA, Li Y, Lliu H, Moezi L, Baik SK, Lee SS. Local production of endocannabinoids is increased in the cirrhotic rat heart [Abstract]. HEPATOLOGY 2004;40:4.
21. Siegmund S, Uchinami H, Osawa Y, Brenner DA, Schwabe RF. Anandamide induces necrosis in primary hepatic stellate cells. HEPATOLOGY 2005;41:1085-1095.
22. Biswas KK, Sarker KP, Abeyama K, Kawahara K, Iino S, Otsubo Y, et al. Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. HEPATOLOGY 2003;38:1167-1177.
23. Julien B, Grenard P, Teixeira-Clerc F, Tran Van Nhieu J, Li L, Karsak M, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the Liver. Gastroenterology 2005;128: 32-45.
24. Bataller R, Ros J, Jimenez W, Brenner DA. Anandamide, an endogenous cannabinoid, inhibits contraction proliferation and migration of human hepatic stellate cells [Abstract]. J Hepatol 2004;40:94.